PathGroup Acquires Pathology Consultants, Continuing Expansion Across the Southeastern United States

“PathGroup and Pathology Consultants are complementary partners with shared values. Together we will provide the highest-quality pathology services to our clients and patients,” said David P. Schammel, M.D., Medical Director of Pathology Consultants. “We look forward to working with PathGroup to continue to exceed the expectations of our health systems and physician clients.”

PathGroup, one of the largest providers of anatomic pathology, digital pathology, clinical and molecular laboratory services in the United States, announced the acquisition of Pathology Consultants, a leading provider of pathology services based in Greenville, S.C.

The combination of PathGroup and Pathology Consultants brings together two market leaders with deep histories of highly specialized pathology expertise, while adding PathGroup’s broader offering of clinical and molecular services for existing Pathology Consultants clients. Together, PathGroup and Pathology Consultants will provide physicians and patients across the Southeast with superior quality and service levels for their comprehensive testing needs.

“We welcome Pathology Consultants to the PathGroup family of more than 225 pathologists,” said Ben W. Davis, M.D., Chief Executive Officer of PathGroup. “Our companies share a 50-year legacy of proven commitment to our clients and patients, along with a culture of physician leadership. Together with the industry-leading health systems and practices of Pathology Consultants, we will continue providing highly specialized pathology expertise, as well as a broad range of clinical and molecular pathology services.”

“PathGroup and Pathology Consultants are complementary partners with shared values. Together we will provide the highest-quality pathology services to our clients and patients,” said David P. Schammel, M.D., Medical Director of Pathology Consultants. “We look forward to working with PathGroup to continue to exceed the expectations of our health systems and physician clients.”

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.